Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
Completed
National Institute of Mental Health (NIMH)
Phase 4
2002-02-01
This study will evaluate the safety and efficacy of risperidone (Risperdal®), olanzapine
(Zyprexa®), and molindone (Moban®) for the treatment of children and adolescents with
schizophrenia or schizoaffective disorder.
Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
Completed
University of North Carolina, Chapel Hill
Phase 4
2002-02-01
This study will evaluate the safety and efficacy of risperidone (Risperdal®), olanzapine
(Zyprexa®), and molindone (Moban®) for the treatment of children and adolescents with
schizophrenia or schizoaffective disorder.
Open-label, extension study for subjects that completed 810P202 to examine long term safety
and tolerability of repeated dosing of SPN-810M as an adjunctive therapy in children with
Impulsive Aggression Comorbid with Attention-Deficit/Hyperactivity Disorder (ADHD).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
